Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation

References

• Shea JB, Sears SF. Cardiology patient pages. A patient’s guide to living with atrial fibrillation. Circulation 2008;117:e340-3
   PubMed Web of Science ®Google Scholar
• American Heart Association. What is atrial fibrillation? Available at: http://www.heart.org/HEARTORG/ Conditions/Arrhythmia/AboutArrhythmia/What-is-Atrial-Fibrillation-AFib-or-AF_UCM_ 423748_Article.jsp, last reviewed April 16, 2014. Accessed September 12, 2014
   Google Scholar
• Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):429S-56S
   Web of Science ®Google Scholar
• Reynolds MR, Essebag V. Economic burden of atrial fibrillation: Implications for Intervention. Am J Pharm Benefits 2012;4:58-65
   Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Johnson B, Smoyer-Tomic K, Siu K, et al. Readmission among hospitalized patients with nonvalvular atrial fibrillation. Am J Health-Syst Pharm 2013;70:414-22
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014 Mar 28. 2014;64(21):2246-80
   Google Scholar
• Chambers S, Chadda S, Plumb J. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. 2009. Int J Lab Hem 2010;32:427-42
   PubMed Web of Science ®Google Scholar
• Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9
   PubMed Web of Science ®Google Scholar
• Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-8
   PubMed Web of Science ®Google Scholar
• Hart RG, Sherman DG, Easton JD, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51:674-81
   PubMed Web of Science ®Google Scholar
• Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17:232-7
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of International Normalized Ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37
   PubMed Web of Science ®Google Scholar
• Björholt I, Andersson S, Nilsson GH, et al. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract 2007;8:6-13
   PubMedGoogle Scholar
• Song X, Sander SD, Johnson BH, et al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health-Syst Pharm 2012;69:329-38
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8
   PubMed Web of Science ®Google Scholar
• Waller D. How VA hospitals became the best. Time 2006;168:36-7
   PubMedGoogle Scholar
• VA Information Resource Center: VIReC The Researcher’s Guide to VA data. Medical SAS datasets. Available at: http://www.virec.research.va.gov/MedSAS/Overview.htm#Data. Accessed May 1, 2014
   Google Scholar
• VA Information Resource Center; VIReC Research User Guide: VHA Decision Support System Clinical National Data Extracts. 2nd ed. Hines, IL: US Dept. of Veterans Affairs, Health Services Research and Development Service, VA Information Resource Center, Sept. 1, 2009. Available at: http://www.virec.research.va.gov/References/RUG/RUG-DSS-2nd-Ed-er.pdf. Accessed May 1, 2014
   Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinical settings: a multi-site managedcare study. Ann Pharmacother 2005;39:446-51
   PubMed Web of Science ®Google Scholar
• Limone, BL, Baker WL, Mearns ES, et al. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation. J Clin Epidemiol 2014;67:1093-102
   Google Scholar
• Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-52
   PubMed Web of Science ®Google Scholar
• Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 2009;27:293-9
   Google Scholar
• Aziz F, Corder M, Wolffe J, et al. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011;25:1404-7
   Google Scholar
• Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ 2014;348:G2116
   PubMedGoogle Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar